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Diabetic bacterial foot infections (DBFIs) are limb-threatening complications in patients with diabetes mellitus, accounting for 50% of diabetes related lower 
limb amputations in developing countries, representing approximately 20 percent of all diabetes-related hospital admissions with significant healthcare-related 
costs involved. The widespread problem of bacterial resistance to most commonly used antibiotics places a huge economic burden on the healthcare system, 
with both increased morbidity and mortality among diabetic patients with foot infections. In this study, the antibacterial activity of organic extracts of the fresh 
liverwort Marchantia debilis from the North West Region of Cameroon is reported. An exit pool system, where patients presenting with DBFIs consented to 
be involved in the use of phytomedicines, after long term treatment of ulcers with antibiotics and not yielding significant long term benefit, presented 
themselves at the Phytobiotechnology Research clinic (PRF). Continuous culture of swabs from foot and toe wounds from 30 infected patients on nutrient agar 
and MacConkey agars in triplicate as well as Gram stain microscopy, revealed the presence of Staphylococcus aureus, Pseudomonas aeruginosa, Escherichia 
coli, Proteus mirabilis and Bacillus species. Light petroleum and methanol extracts of the whole bryophyte plants at 100% concentration were tested. In vitro 
inhibition of the tested bacterial isolates from the diabetic foot ulcers by M. debilis was observed only with the light petroleum extract. No inhibition by the 
extracts was observed for the Pseudomonas aeruginosa isolate. The light petroleum extract of M. debilis was formulated into a petroleum oil based cream 
named BryoCreamTM. This was administered to 20 of the patients with 90% cure rate in a three week time period. The main nonpolar components were 
determined by GCMS as lepidozene and β-barbatene, and by NMR as stigmasterol and β-sitosterol. In conclusion, nonpolar extracts from bryophytes from 
Cameroon could, potentially, be used to treat diabetic bacterial foot infections. 
 




Many bioactive compounds have been isolated from bryophytes, 
especially liverworts originating from Asia, Europe and South 
Africa [1-3]. For example, Adio et al. [1] and Allison and Chud [3] 
identified a number of such compounds from liverworts in New 
Zealand. Volatile constituents have been identified in liverworts 
including Tritomaria polita, Marsupella emarginata, M. aquatica 
and M. alpina. 
 
Asakawa and colleagues [4-6] reported that bryophytes are 
potentially rich in compounds such as sesqui- and diterpenoids, 
bibenzyls and bisbibenzyls, as well as flavonoids, with allergenic 
contact dermatitis, antimicrobial, antifungal, cytotoxic, insect 
repellent, insecticidal, molluscidal, cardiotonic and muscle relaxing 
activities. Bryophytes are very common across Africa, particularly 
in Cameroon. 
 
Diabetes mellitus (DM) is projected to affect a staggering figure of 
552 million people in 2030 as compared with 371 million in 2011. 
A few decades ago, DM was considered as a disease of affluent 
societies. Today, it is known that most of the world’s diabetes 
patients live in developing countries [7-9]. As such, with the recent 
rising incidence of this condition, the developing world, the African 
continent, including Cameroon, has been hard hit by this pandemic, 
and is experiencing an exponential rise in its incidence, as well as 
its burdens. Again, estimates suggest a giant leap from 14 million 
diabetics in 2012 to 28 million for sub-Saharan Africa in 2030, with 
as many as 85% of the cases largely undiagnosed. The WHO 
African Region describes the impact and devastating outcomes of 
diabetes in the region as one of Africa’s New Silent Killers. 
 
Treatment of diabetic foot infections in sub-Saharan Africa and 
throughout the world is very challenging due to slow healing and 
increasing antibiotic resistance [10-12]. The drugs of choice for the 
systemic treatment of DFIs are mostly cloxacillin, ciprofloxacillin, 
and azithromycin and gentamicin [13-15], and topically using 
bacitracin powder and antiseptics such as alcohols [16-18]. These 
drugs of choice and antiseptics are proving to be ineffective for 
sustained DFI treatment. Antibiotic resistance in clinical treatment 
of diseases in Africa is rising exponentially [19-22]. Consequently, 
the need to explore alternative antimicrobials for DFIs is exigent 
[23-28]. Plants, particularly lower plants, which have often been 
ignored, could provide new drug leads for the treatment of DFIs. 
The ecology of Cameroon is rich in algae, hornworts, lichens, 
mosses and liverworts, especially since the country lies in the 
Congo forest and with Mount Cameroon harboring a rich 
biodiversity of both lower and higher plants. A quick survey of 
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bryophytes in Cameroon reveals many unidentified species, with 
familiar species such as Marchantia sp. The main objective of this 
study was to provide a preliminary report on the application of the 
light petroleum extract of the liverwort M. debilis from Cameroon 
in the treatment of DFIs, both in vitro and in vivo. 
 
Table 1 shows the various bacterial isolates that are prevalent 
among the patients presenting with DFI. Staphylococcus aureus was 
the most frequently isolated in this study, followed by Pseudomonas 
aeruginosa. Most of the isolates that make up DFBI among the 
patients were Gram-negative bacterial infections. These bacteria are 
generally resilient and easily tolerate antibiotics. The isolated 
bacteria in this study and their distribution are very important, as 
many general medical practitioners make prognostic treatments of 
DFIs without proper culture of the exudates and proper etiologic 
agents, as well as a rigorous antibiotic sensitivity profile. The 
infective organisms of DFIs in Africa have not been well studied, 
and the microbial isolates may not be known thoroughly. 
 
Table 1: DBFI isolates from 30 patients with bacterial frequency in percent. 
DBF isolate from patients Frequency of occurrence on 30 patients (%) 
Staphylococcus aureus 45 
Proteus mirabilis 10 
Bacillus sp. 5 
Pseudomonas aeruginosa 25 
Escherichia coli 15 
 
In earlier investigations, several sesquiterpenes and sterols have 
been detected in extracts of Marchantia species [4]. Asakawa [4-7] 
reported the isolation and structural determination of secondary 
metabolites of several hundred species of bryophytes (including 
Marchantia sp.) collected from all over the world and a number of 
interesting biological activities were reported of sesqui- and 
diterpenoids and complex aromatic compounds like bisbibenzyls, as 
mentioned earlier. 
 
Table 2: Antibacterial activity of the petroleum and methanol extracts of Marchantia 
debilis as zones of inhibition (Average of duplicates in mm). 
Extract S. aureus E. coli P. aeruginosa Bacillus sp. 
Light petroleum extract 15 12 0 17 
 Light petroleum, control 15 12 0 17 
Methanol extract 0 0 0 0 
Methanol control 0 0 0 0 
 
In this work our goal was to test one nonpolar (light petroleum) and 
one polar (methanol) extract of M. debilis. The results show that the 
light petroleum extract possessed antibacterial ingredients (Table 2), 
whereas the methanol extract was inactive. This suggests that the 
active ingredients are nonpolar compounds. GCMS analyses 
revealed two dominant components in the nonpolar (diethyl ether) 
extract of M. debilis: lepidozene and β-barbatene. Analyzing the 13C 
NMR spectra of different fractions of the n-hexane extract of M. 
debilis, beside fatty acids, showed stigmasterol as the most 
dominant component of the sterol fractions; β-sitosterol was also 
recognized [33]. Although it is known that stigmasterol and β-
sitosterol possess antibacterial and anti-inflammatory activity [34-
37] we cannot ascribe to them the effectiveness of bryocream since 
they were present in the methanol extract as well, which was not 
active. Further investigation is necessary. 
 
The secondary metabolites of bryophytes from Africa, including 
Cameroon, have not been widely studied. In other studies using 
higher plants and mushrooms, Yongabi et al. [29, 30] reported the 
activity of a number of medicinal plant extracts on yeast isolates 
from clinical specimens from HIV patients in Cameroon. Table 3 
shows that the bryophyte based preparation was effective (90%) in 
the treatment of DFIs among patients in Cameroon.  
 
Table 3: In vivo evaluation of Bryocream and ointment on patients with DFIs at PRF 
clinics. 
Kind of  
DFIs 
No. of  
patients No. cured 
Percentage 
cured* (%) Duration of treatment (days) Status 
Foot ulcers 20 18 90 7-10 All diabetic
*With a patient whose wound got completely dried. 
 
  Figure 1: DFI ulcer (left), and after treatment with Bryocream and ointment (right) 
after 14 days. 
 
Figure 1 shows a classical foot ulcer that was treated in this study in 
about 14 days when both the cream and ointment was applied daily. 
This is promising, and is the first report on the use of the bryophyte 
flora of Cameroon to attend to diabetic bacterial foot infections. The 
conclusion is drawn that these bryophyte medicated products may 
offer a comparatively cheaper, safer and effective approach to 
managing diabetic foot bacterial infections in sub-Saharan Africa 




Criteria for specimen collection: The diabetic patients opted to be 
treated using naturopathic therapy that was developed at the PRF 
research station. PRF is a registered research non-Governmental 
Organization with the Cameroon Government and is registered with 
the European Union. Specimen collection and tests were based on 
the complaints given by the patients, as well as para-clinical 
examinations. Patients without symptoms and signs of diabetes, and 
without a DFI were excluded from this study. Ethical consideration 
for this study was given by the CBC Health Board in Cameroon, 
with approval number IRB 2013-10, August 3, 2013. 
 
Specimen collection: The patients were all diabetic, whose status 
was confirmed at the Bamenda regional hospital. All were receiving 
glucophage, insulin and metformin, and were re-confirmed at the 
PRF Clinics using the onestop glucose testing kit, a commercial kit. 
Thirty diabetic patients through an exit pool were considered. 
Swabs were collected from the affected wounds and ulcers using 
sterile swab sticks and the specimens appropriately labeled using a 
bold marker and serial number assigned to represent each patient’s 
name. 
 
Microscopic examination and culture of swabs and necrotic 
debris: The specimens were appropriately processed using the 
Gram stain method [9], and portions of each specimen were 
cultured aseptically by streaking onto nutrient and MacConkey 
agars and incubated at room temperature at 37ºC for 36 h according 
to established methods [9, 29]. Plates were examined for their 
morphology and micro morphology [30]. 
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Sources, identification and processing of collected bryophytes: M. 
debilis Goebel, was collected from the banks of streams around 
raffia bushes at w3Mendakwe, Bamenda, North West region of 
Cameroon. Voucher specimen was taken and identified by 
biologists at CCast Bambili and confirmed by Y.A. The plant 
material was carefully washed, followed by crushing in a mortar 
using a pestle, and passed through sieves of 3 mm mesh. Voucher 
samples were stored at the Phytobiotechnology Research 
Laboratory, Bamenda, Cameroon. 
 
Extraction procedures  
 
Extraction for making biocream: Liverwort (50 g) was added 
separately to methanol and light petroleum, 250 mL (1:5, w/v) in 
beakers, and allowed to extract for 72 h at room temperature [13, 
29]. The extracts were filtered through Whatman filter paper no 1 
(Whatman, UK) and the filtrate was evaporated under vacuum at 
38ºC. The resulting dried extracts were stored in sterile, screw 
capped bottles and kept at room temperature. 
 
Extraction for GCMS analysis: Dried plant material was carefully 
purified, crushed in a mortar using a pestle, and extracted with 
diethyl ether for 30 min. An ultrasonic bath was used for the first 5 
min of extraction. After extraction, the extract was filtered through 
filter paper and then through a glass pipette filled with silica gel to 
remove traces of water. After dilution with n-hexane, the solution 
was analyzed by GCMS conducted on an Agilent Technologies 
6890N gas chromatograph coupled with a mass detector (Agilent 
Technologies 5973), provided with a DB 5 (30 m × 0.25 mm ID × 
0.25 μm df) capillary column. The analyses were performed in EI mode (70eV) using He at 1 mL/min. The injection temperature was 
set at 250ºC. The analyses were carried out using a temperature 
program starting from 50ºC with an initial 5 min hold to 250ºC, 
with a 10ºC/min heating increase and keeping the final temperature 
stable for 20 min. The mass range was set at m/z 40-500 with 3 
scans. The transfer line was set at 280ºC. Co-injection of the 
extracts with C9-C25 hydrocarbons was performed under the same 
conditions. 
 
Extraction for NMR analysis: Dried and purified plant material 
was crushed in a blender and extracted with n-hexane for 24 h. An 
ultrasonic bath was used for the first 1 h of extraction. After 
extraction, the extract was filtered through a filter paper to remove 
the remaining plant material. NMR spectra were recorded on a 
Varian 500-PS NMR instrument at 500 MHz for 1H and 125 MHz 
for 13C in CDCl3.  
 
Determination of antibacterial activity of the extracts: The agar 
diffusion method according to Yongabi and colleagues [32] was 
employed. A sample (0.2 g) of the M. debilis extract was 
reconstituted in distilled water (5 mL). Antibiotic susceptibility was 
determined by the agar well diffusion method as commonly used 
and standardized in the US by the National Committee for Clinical 
Laboratory Standards (NCCLS). The zone of inhibition was 
measured and the results interpreted as sensitive, intermediate 
resistant, or resistant. The zone sizes of inhibition were measured 
and interpreted using the NCCLS, as recommended by WHO [9]. 
Each extract was incorporated in a 6 mm well previously bored 
using a steel borer. Controls were set up by introducing the 
extraction solvents (methanol and light petroleum) into different 
wells. The plates were incubated at 37ºC for 36 h. The development 
of inhibition by the extracts against the test organism was measured 
[9, 29, 30, 31] The differences between the inhibition rates of the 
extracts, the test, and that of the control were recorded as the actual 
diameter of zones of inhibition caused by the extract [31, 32]. The 
solvents, methanol and light petroleum did not exhibit any 
inhibition in this study. 
 
Preparation of bryophyte-based cream: The organic extracts (200 
mg) of M. debilis were blended into 200 g of Petroleum jelly 
following standard chemical techniques reported previously by 
Yongabi [31]. 
 
Preparation of bryophyte extracts based ointment using olive oil 
base: The organic extracts (200 mg) of M. debilis were blended into 
olive oil and palm kernel oil (200 mL). Standard organic chemistry 
protocols, as described by Yongabi et al. [30] were applied. 
 
Administration of bryophyte cream and ointment to patients 
recruited in the study versus placebo group: Twenty diabetic 
patients from PRF clinics and other local clinics in the North West 
Region of Cameroon were enrolled for management of their wound 
with BryocreamTM, a M. debilis extract based therapy, developed at 
the Phytobiotechnology Research Clinic, Bamenda, Cameroon. 
Patients’ wounds were cleaned through swabbing with distilled 
water, and with no antiseptics, as traditionally done. Appropriate 
culture tests for proper etiologic identification were made before the 
products were applied. A positive control cream formulated with 
methanol and light petroleum was also used. The 20 patients were 
properly educated on the mode of administration and asked to report 
on a weekly basis for observation and follow up. Each patient 
received a screw capped bottle containing a cream and another 
containing the ointment. A sample (20 g) of the cream was 
administered daily after application of the ointment (5 mL) for a 3 
weeks maximum therapeutic period. Follow up was terminated 
when the infection wound dried up. It was resolved that the patients 
should present for re-examination at our clinic periodically. 
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